par Van Laethem, Jean-Luc ;Van Maele, Ph;Verslype, Chris;Polus, Marc;Demols, Anne ;Houbiers, Ghislain;Caenepeel, P.;Leleux, A.;Vermaut, R R;Van Cutsem, Eric;Peeters, Marc
Référence Oncology, 67, 5-6, page (338-343)
Publication Publié, 2004
Référence Oncology, 67, 5-6, page (338-343)
Publication Publié, 2004
Article révisé par les pairs
Titre: |
|
Auteur: | Van Laethem, Jean-Luc; Van Maele, Ph; Verslype, Chris; Polus, Marc; Demols, Anne; Houbiers, Ghislain; Caenepeel, P.; Leleux, A.; Vermaut, R R; Van Cutsem, Eric; Peeters, Marc |
Informations sur la publication: | Oncology, 67, 5-6, page (338-343) |
Statut de publication: | Publié, 2004 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Adenocarcinoma -- drug therapy -- secondary |
Adult | |
Aged | |
Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use | |
Belgium | |
Deoxycytidine -- administration & dosage -- analogs & derivatives | |
Disease-Free Survival | |
Drug Administration Schedule | |
Female | |
Humans | |
Male | |
Middle Aged | |
Pancreatic Neoplasms -- drug therapy -- pathology | |
Quinazolines -- administration & dosage | |
Survival Analysis | |
Thiophenes -- administration & dosage | |
Treatment Outcome | |
Note générale: | Clinical Trial |
Clinical Trial, Phase II | |
Journal Article | |
Multicenter Study | |
Research Support, Non-U.S. Gov't | |
Langue: | Anglais |
Identificateurs: | urn:issn:0030-2414 |
info:doi/10.1159/000082916 | |
info:pii/82916 | |
info:scp/13844307892 | |
info:pmid/15713988 |